The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

To counteract these challenges, novel strategies aim to restore the cancer immunity cycle. One approach involves directly injecting unadjuvanted influenza vaccines or drug-loaded oncolytic viruses ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) ...

The mRNA vaccine against avian influenza presents several advantages and disadvantages: Advantages: Rapid Development and Production; Non-Infectious Nature; Strong Immune Response; Adaptability to ...

Researchers have found a new way to reduce the effects of pre-eclampsia using mRNA-lipid nanoparticle therapies.

"Everything injected into the bloodstream is eventually ends up in the liver — that's just how our anatomy works," Professor ...

Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...

Every time a shuttle docks with the International Space Station (ISS), a precise and intricate process takes place between ...

The findings suggest that lipid composition can direct mRNA-based drugs to target organs, such as the intestines, without passing through the liver.